HepQuant AI™
HepQuant has a unique sample repository of over 15,000 biological samples coupled with HepQuant results. The company is currently pursuing an initiative to implement modalities of artificial intelligence to create new AI-based liver function optimizations of HepQuant technology. HepQuant and Dr. Michael P. McRae presented a poster at the EASL 2022 International Liver Congress in London related to a compartmental model in development that will form the basis for future AI development.
If you are interested in partnering or collaborating around these initiatives, please contact us.
Related Liver Test Studies Posters
Poster: The HepQuant’s Disease Severity Index (HepQuant DSI™) Outperforms Child-Pugh (CP) Classification in Quantifying Hepatic Impairment for Prediction of Drug Pharmacokinetics (PK) In Chronic Liver Disease
Poster: The HepQuant’s Disease Severity Index (HepQuant DSI™) Outperforms Child-Pugh (CP) Classification in Quantifying Hepatic Impairment for Prediction of Drug Pharmacokinetics (PK) In Chronic Liver Disease
